#### INTERLEUKIN GENETICS INC

Form 4

December 24, 2014

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

Check this box if no longer

January 31, Expires: 2005

**OMB APPROVAL** 

subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Estimated average burden hours per response...

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

Common

Common

Stock

(Print or Type Responses)

1. Name and Address of Reporting Person \*

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

BAY CITY CAPITAL LLC

Symbol INTERLEUKIN GENETICS INC

(Check all applicable)

[ILIU]

(Middle)

(Zip)

3. Date of Earliest Transaction

Director Officer (give title

10% Owner Other (specify

750 BATTERY STREET, SUITE

(Street)

(State)

(First)

400

12/23/2014

(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

4. If Amendment, Date Original

Applicable Line) Form filed by One Reporting Person

\_X\_ Form filed by More than One Reporting

Person

0.1003

below)

SAN FRANCISCO, CA 94111

(City)	(State)	(Zip) Ta	able I - Non	-Derivative Securities Acquired	l, Disposed of, or	Beneficially	Owned
1.Title of	2. Transaction Date	2A. Deemed	3.	4. Securities Acquired (A) or	5. Amount of	6.	7. Natur
Security	(Month/Day/Year)	Execution Date, if	Transaction	orDisposed of (D)	Securities	Ownership	Indirect
(Instr. 3)		any	Code	(Instr. 3, 4 and 5)	Beneficially	Form:	Benefici
		(Month/Day/Year)	(Instr. 8)		Owned	Direct (D)	Ownersh
					Following	or Indirect	(Instr. 4)
					Danartad	(I)	

3.	4. Securities Acquired (
Transactio	orDisposed of (D)
Code	(Instr. 3, 4 and 5)
(Instr. 8)	

5. Amount of
Securities
Beneficially
Owned
Following
Reported
Transaction(s)

7. Nature of Ownership Indirect Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4)

(A) or (Instr. 3 and 4) Price Amount

A

(D) Code V

25,996,552

See 46,184,016 footnotes (1)(2)

(Instr. 4)

(I)

I

12/23/2014 Stock

12/23/2014

P 495,400

P

880,099

See footnotes (1)(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

SEC 1474 (9-02)

# Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

#### number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A) (D	Date Exercisable	Expiration Date	Title	Amo Num Shar
Common Stock Warrant (right to buy)	\$ 0.1003	12/23/2014		P	25,996,552	12/23/2014	12/23/2021	Common Stock	25,
Common Stock Warrant (right to buy)	\$ 0.1003	12/23/2014		P	495,400	12/23/2014	12/23/2021	Common Stock	49

# **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
BAY CITY CAPITAL LLC 750 BATTERY STREET, SUITE 400 SAN FRANCISCO, CA 94111		X			
Bay City Capital Fund V, L.P. 750 BATTERY STREET, SUITE 400 SAN FRANCISCO, CA 94111		X			
Bay City Capital Fund V Co-Investment Fund, L.P. 750 BATTERY STREET, SUITE 400 SAN FRANCISCO, CA 94111		X			
Bay City Capital Management V LLC 750 BATTERY STREET, SUITE 400 SAN FRANCISCO, CA 94111		X			
Signatures					

\*\*Signature of Reporting Person

/s/ Michael Lawhead,

attorney-in-fact

Date

12/24/2014

Reporting Owners 2

### Edgar Filing: INTERLEUKIN GENETICS INC - Form 4

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - Bay City Capital LLC, a Delaware limited liability company ("BCC"), Bay City Capital Management V LLC, a Delaware limited liability company ("Management V"), Bay City Capital Fund V, L.P., a Delaware limited partnership ("Fund V"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership ("Co-Investment V"), are deemed to be a "group" for the purpose of Section
- (1) 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V.
- (2) Represent securities held by Fund V, including indirect interests of Management V. Management V disclaims beneficial ownership with respect to these securities, except to the extent of its pecuniary interest therein.
- (3) Represent securities held by Co-Investment V, including indirect interests of Management V. Management V disclaims beneficial ownership with respect to these securities, except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.